

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1430 Alexandra, Virginia 22313-1450 www.wepto.gov

ELECTRONIC

01/11/2011

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/558,409	8,409 11/28/2005 Avraham Shekalim		2894/13	6269	
44696 DR. MARK M.	7590 01/11/201 FRIEDMAN	EXAMINER			
C/O BILL POLKINGHORN - DISCOVERY DISPATCH			STIGELL, THEODORE J		
	9003 FLORIN WAY UPPER MARLBORO, MD 20772			PAPER NUMBER	
			3763		
			NOTIFICATION DATE	DELIVERY MODE	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mark_f@friedpat.com nomi_m@friedpat.com friedpat.uspto@gmail.com

Office Action Summary

Application No.	Applicant(s)			
10/558,409	SHEKALIM, AVRAHAM			
Examiner	Art Unit			
THEODORE J. STIGELL	3763			

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply

eamed	patent	term	adjustim	ent.	266 37	CFR	1.7U4(D

	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extremore of time may be available under the provisions of \$7.0FH 1.130(a). In no event, however, may a reply be timely filled after \$N(a) MONTH's from the mailing date of this communication.
	If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (8) MONTHS from the malling date of this communication. Failure to engly with the sate or excented period for reply will, by statute, cause the application to become ABANDONED (38 U.S.C.§ 133). Any reply received by the Office later than these months after the mailing date of this communication, even if timely filled, may reduce any earned patient term adjustment. See 37 CFR 17.0400.
St	atus
	1) Responsive to communication(s) filed on <u>27 October 2010</u> .
	2a) This action is FINAL . 2b) This action is non-final.
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Exparte Quayle, 1935 C.D. 11, 453 O.G. 213.
Di	sposition of Claims
	4) Claim(s) 1-32 is/are pending in the application.
	4a) Of the above claim(s) <u>25-29</u> is/are withdrawn from consideration.
	5) Claim(s) is/are allowed.
	6)⊠ Claim(s) <u>1-24 and 30-32</u> is/are rejected. 7)□ Claim(s) is/are objected to.
	8) Claim(s) is are subjected to.
۱į	oplication Papers
۱ţ	9) The specification is objected to by the Examiner.
٧ţ	. 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.
Λþ	. 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
۸ţ	9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
γţ	. 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
•	9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
•	9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.
•	9) The specification is objected to by the Examiner. 10) The drawing(s) filed on
•	9) The specification is objected to by the Examiner. 10) The drawing(s) filed on
•	9) The specification is objected to by the Examiner. 10) The drawing(s) filed on
•	9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. itority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
•	9) The specification is objected to by the Examiner. 10) The drawing(s) filed on
•	9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. itority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
•	9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. itority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

Attachment(s)		
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)	
2) Notice of Draftsporson's Fatent Drawing Review (PTO-942)	Paper No(s/Mail Date.	
Information Disclosure Statement(s) (PTO/SB/08)	 Notice of Informal Patent Application 	
Paner Na/a/Mail Date 9/2/2006 7/9/2010	e) Other:	

Application/Control Number: 10/558,409 Page 2

Art Unit: 3763

DETAILED ACTION

Election/Restrictions

Applicant's election without traverse of Group I (claims 1-24 and 30-32) in the reply filed on 10/27/2010 is acknowledged.

Claims 25-29 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Specification

The disclosure is objected to because of the following informalities:

• On line 8 of page 12, there is an apparent typo (reservoir 12).

Appropriate correction is required.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filled in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filled in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 17 and 19 are rejected under 35 U.S.C. 102(e) as being anticipated by Holst et al. (US 6,497,680).

Holst discloses in a drug delivery device (10) having a pressurized source of a liquid medicament supplying a flow path including two valves (18, 32) and a flow

Application/Control Number: 10/558,409

Art Unit: 3763

restriction (30), a method for identifying malfunction of at least one of the valves (see column 17, line 51-column 18, line 16), the method comprising (a) closing both valves in such a manner as to ensure a pressure differential across at least one of the valves; and (b) monitoring for a change in liquid pressure between the valves, wherein said monitoring includes measuring a pressure differential between said pressurized source and liquid between the valves.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory

Application/Control Number: 10/558,409

Art Unit: 3763

double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-21 and 30-32 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 7,291,126. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are broader in scope and therefore overlap with the patented claims.

Claims 22-24 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims of U.S. Patent No. 7,377,907.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims overlap in scope with the patented claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to THEODORE J. STIGELL whose telephone number is (571)272-8759. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor. Nicholas Lucchesi can be reached on 571-272-4977. The fax phone Application/Control Number: 10/558,409 Page 5

Art Unit: 3763

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Theodore J Stigell/ Primary Examiner, Art Unit 3763